Clinical Trials
6 trialsNCT05494580 2026-03-10
Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer
Sun Yat-sen University
Phase 1/2 Completed
NCT05044871 2025-06-08
BRIGHT
Tongji Hospital
Phase 2 Completed
NCT05652283 2024-11-27
Pamiparib Combined With Surufatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer
Anhui Provincial Cancer Hospital
Phase 2 Active not recruiting
NCT05489926 2024-01-26
A Study to Explore Pamiparib Treatment in Epithelial Ovarian Cancer After Prior PARP Inhibitor Exposure
Zhejiang Cancer Hospital
Phase 2 Unknown
NCT05669768 2023-01-03
Study on the Efficacy and Toxicity of Pamiparib Combined With Tamoxifen in the Treatment of Epithelial Ovarian Cancer Patients With Biochemical Recurrence During First-line PARPi Maintenance Therapy
Sun Yat-sen University
Phase 2 Unknown
NCT03933761 2021-08-10
PRECISE
Australia New Zealand Gynaecological Oncology Group
Phase 2 Withdrawn